BioPharma Resources

Drug Trial Radar · NCT05418673

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants

Last checked: Nov 19, 2026Latest source record: Jun 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

7

Actual

Start

Aug 26, 2022

Primary completion

Jul 27, 2023

Study completion Jul 27, 2023

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Denali Therapeutics Inc.
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). The study will focus on participants with a specific genetic variant in their LRRK2 gene. The main question researchers are trying to answer is if taking BIIB122 slows the worsening of PD more than placebo in the early stages of PD. To help answer this question, researchers will use a questionnaire called the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, also known as the MDS-UPDRS. * The MDS-UPDRS measures impairment and disability in people living with PD. It was created in the 1980s and is one of the most used rating scales for PD symptoms. * The MDS-UPDRS has 4 parts, and a higher score means more severe PD symptoms. * Part I assesses non-motor experiences of daily living, including but not limited to memory loss, problems sleeping, pain, depression, and anxiety. * Part II measures motor experiences of daily living. * Part III is the results of a motor symptoms exam by a medical professional. * Part IV records PD complications caused by motor symptoms. Researchers will also learn more about the safety of BIIB122. A description of how the study will be done is given below. * Participants will take BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but contains no real medicine. * Participants will be in the study for 103 weeks to 187 weeks. This includes the screening and follow-up periods. * Participants will take BIIB122 or placebo 1 time a day for 96 to 180 weeks. * Participants can continue to take certain medications for PD. Participants must be on the same dose of medication for at least 90 days before the study begins. * Participants will visit the clinic less often as the study continues, ranging every 4 weeks to every 24 weeks.

Conditions

  • Parkinson Disease

Interventions

  • BIIB122Drug

    Administered as specified in the treatment arm.

  • BIIB122-Matching PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and IIITime frame: From Week 96 to Week 180

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California San Francisco (UCSF)

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Rocky Mountain Movement Disorders Center, PC

    Englewood, Colorado

  • Parkinson's Disease and Movement Disorders Center

    Boca Raton, Florida

  • USF Health Byrd Institute

    Tampa, Florida

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mount Sinai Beth Israel

    New York, New York

  • Weill Medical College of Cornell University

    New York, New York

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Evergreen Hospital Medical Center

    Kirkland, Washington

  • Inland Northwest Research

    Spokane, Washington

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France

  • Hôpital de la Timone

    Marseille, Bouches-du-Rhône, France

  • Hopital Purpan

    Toulouse, Haute Garonne, France

  • CHU Rennes - Hopital Pontchaillou

    Rennes, Ille Et Vilaine, France

  • Centre Hospitalier Universitaire de Lyon-Hospices Civils de Lyon-Hopital Pierre Wertheimer

    Bron, Rhone, France

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, Germany

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, Germany

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital General de Catalunya

    Sant Cugat del Vallès, Barcelona, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Guipuzcoa, Spain

  • Ninewells Hospital

    Dundee, Tayside Region, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.